| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.38 | 0.004 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.16 | 0.004 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.36 | 0.004 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.005 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.098 | 0.007 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.091 | 0.007 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.1 | 0.008 |